BioGAL Advanced Biotechnology Ltd. (now XTL)

www.bio-gal.com

High-Tech Company

Acquired by XTL

TECH VERTICALS

Life Sciences, MedTech, Pharmaceuticals, Therapeutics

General Data

Sector	Biomed
Company Stage:	R&D
Established	2001
Number of Employees	9
Reg. Number:	abCDe

DESCRIPTION

BioGAL is a market-driven developer of drug applications for cancer. The company has patented (PCT, pending) the use of Erythropoietin (Epo) against Multiple Myeloma(MM), an incurable hematological cancer of plasma cells. Clinical observations in human patients and research in animals have shown that Epo could be highly effective in MM. BioGAL is also examining the effect of Epo on additional potential cancer types.

TECHNOLOGY

Erythropoietin (Epo)

Products and Phases

Product	Phase
Erythropoietin (Epo)	Phase I
Epo is a drug against Multiple Myeloma(MM), an incurable hematological cancer of plasma cells.

	TARGET MARKETS
	Pharmaceutical Companies.HMOs,Hospitals,Multiple Myeloma Market

	BUSINESS MODEL
	B2B

CONTACT INFO

Expand / Collapse All

Main Address: Tel Aviv, Israel

Address	38 Habarzel St.
City	Tel Aviv
Country	Israel
Zip	69710

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Pini Ben-Elazar	Co-Founder	Mor Research Applications (CEO)
Mr. David Bassa	Co-Founder
Prof. Moshe Mittelman	Co-Founder	XTL (Medical Director)

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	President & Founder, BioGAL

Mergers & Acquisitions

Round

Date

Stage

Amount

Valuation

Acquired

Jan. 17, 2010

abCDe

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors